Publikationen

Daniel Engels, Patrick Schindler, Joachim Havla et al. Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.
Neurology 2026.

Katrin Giglhuber, Alix Bertrand, Clarissa Zappe et al. Unmet needs in the care of patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody associated disease: insights from Germany..
Neurological Research and Practice 2026.

Daria Tkachenko, Ilya Ayzenberg, Louisa M. Schöppe et al. Socioeconomic impact of depression and pain in patients with neuromyelitis optica spectrum disorders.
Neurological Research and Practice 2026.
Zitiert von: 1

Daniel W. Engels, Mariella Herfurth, Joachim Havla et al. Age, Low Immunoglobulin G, and M Serum Levels Predict Infections in People With AQP4-IgG+ NMOSD Treated With Rituximab-A Multicenter Cohort Study From the German Neuromyelitis Optica Study Group (NEMOS).
European Journal of Neurology 2026.

Anna Walz, Daria Tkachenko, Martin W. Hümmert et al. Dyadic Coping of NMOSD and MOGAD patients and their partners: a sociological and psychological examination of strategies (CoMMOnsense-Study).
BMJ Neurology Open 2025.
Zitiert von: 3

Carolin Schwake, Theodoros Ladopoulos, Vivien Häußler et al. Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks.
Journal of Neurology Neurosurgery & Psychiatry 2024.
Zitiert von: 27

Vivien Häußler, Corinna Trebst, Daniel Engels et al. Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD.
Journal of Neurology Neurosurgery & Psychiatry 2025.
Zitiert von: 26

Sarah Passoke, Carlotta Stern, Vivien Häußler et al. Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study).
Journal of Neurology Neurosurgery & Psychiatry 2025.
Zitiert von: 17

Mihaela Nicolescu, Vivien Häußler, Friedemann Paul et al. Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision.
Journal of Neurology 2024.
Zitiert von: 5

Marius Ringelstein, Susanna Asseyer, Gero Lindenblatt et al. Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European Cohort.
Neurology 2024.
Zitiert von: 34

Tania Kümpfel, Katrin Giglhuber, Orhan Aktaş et al. Correction to: Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
Journal of Neurology 2024.
Zitiert von: 11

Ankelien Duchow, Judith Bellmann–Strobl, Tim Friede et al. Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD.
Annals of Neurology 2024.
Zitiert von: 71

Tania Kümpfel, Katrin Giglhuber, Orhan Aktaş et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
Journal of Neurology 2024.
Zitiert von: 244

Sven Jarius, Orhan Aktaş, Ilya Ayzenberg et al. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
Journal of Neurology 2023.
Zitiert von: 218

Martin W Hümmert, Carlotta Stern, Friedemann Paul et al. Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study).
Multiple Sclerosis Journal 2023.

Martin W. Hümmert, Franziska Bütow, Daria Tkachenko et al. Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study.
Neurology Neuroimmunology & Neuroinflammation 2023.
Zitiert von: 11

Martin W. Hümmert, Louisa M. Schöppe, Judith Bellmann-Strobl et al. Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCENMO Study.
Neurology 2022.
Zitiert von: 37

Marius Ringelstein, Ilya Ayzenberg, Gero Lindenblatt et al. Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.
Neurology Neuroimmunology & Neuroinflammation 2021.
Zitiert von: 153

Jonathan Giovannelli, Jonathan Ciron, Mikaël Cohen et al. A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica.
Annals of Clinical and Translational Neurology 2021.
Zitiert von: 44

Ilya Ayzenberg, Daniel Richter, Eugenia Henke et al. Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study of 166 AQP4 Antibody-Seropositive Patients.
Neurology Neuroimmunology & Neuroinflammation 2021.
Zitiert von: 83

Susanna Asseyer, Eugenia Henke, Corinna Trebst et al. Pain, depression, and quality of life in adults with MOG-antibody-associated disease.
European Journal of Neurology 2021.
Zitiert von: 39

Sven Jarius, Christian Lechner, Eva Wendel et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients.
Journal of Neuroinflammation 2020.
Zitiert von: 85

Sven Jarius, Hannah Pellkofer, Nadja Siebert et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients.
Journal of Neuroinflammation 2020.
Zitiert von: 170

Marius Ringelstein, Jens Harmel, Hanna Zimmermann et al. Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders.
Neurology 2020.
Zitiert von: 18

Ingo Kleiter, Anna Gahlen, Nadja Borisow et al. Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions.
Neurology Neuroimmunology & Neuroinflammation 2018.
Zitiert von: 237

Jan‐Patrick Stellmann, Markus Krumbholz, Tim Friede et al. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.
Journal of Neurology Neurosurgery & Psychiatry 2017.
Zitiert von: 152

Nadja Borisow, Ingo Kleiter, Anna Gahlen et al. Influence of female sex and fertile age on neuromyelitis optica spectrum disorders.
Multiple Sclerosis Journal 2017.
Zitiert von: 82

Florence Pache, Hanna Zimmermann, Janine Mikolajczak et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.
Journal of Neuroinflammation 2016.
Zitiert von: 246

Sven Jarius, Ingo Kleiter, Klemens Ruprecht et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
Journal of Neuroinflammation 2016.
Zitiert von: 250

Sven Jarius, Klemens Ruprecht, Ingo Kleiter et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
Journal of Neuroinflammation 2016.
Zitiert von: 896

Sven Jarius, Klemens Ruprecht., Ingo Kleiter et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Journal of Neuroinflammation 2016.
Zitiert von: 433

Ilya Ayzenberg, Joanna Schöllhammer, Robert Hoepner et al. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.
Journal of Neurology 2016.
Zitiert von: 63

Ingo Kleiter, Anna Gahlen, Nadja Borisow et al. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses.
Annals of Neurology 2015.
Zitiert von: 436

Marius Ringelstein, Imke Metz, Klemens Ruprecht et al. Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
Multiple Sclerosis Journal 2014.
Zitiert von: 21

Corinna Trebst, Sven Jarius, Achim Berthele et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).
Journal of Neurology 2014.
Zitiert von: 604

Ingo Kleiter, Kerstin Hellwig, Achim Berthele et al. Is It Too Early to Predict the Failure of Natalizumab in NMO?-Reply.
Archives of Neurology 2012.
Zitiert von: 5

Ingo Kleiter, Kerstin Hellwig, Achim Berthele et al. Failure of natalizumab to prevent relapses in neuromyelitis optica.
Archives of Neurology 2012.
Zitiert von: 296

Sven Jarius, Klemens Ruprecht, Brigitte Wildemann et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.
Journal of Neuroinflammation 2012.
Zitiert von: 771

Corinna Trebst, Achim Berthele, Sven Jarius et al. [Diagnosis and treatment of neuromyelitis optica. Consensus recommendations of the Neuromyelitis Optica Study Group].
Der Nervenarzt 2010.
Zitiert von: 34